BioMedNewsBreaks

MondayOct 09, 2023 12:34 pm

BioMedNewsBreaks – ROTH MKM’s Upcoming Conference to Feature Public Healthcare Companies Across Multiple Sub-Sectors

ROTH MKM, a full-service investment bank focused on serving growth companies and their investors, today announced plans to host its 2023 Healthcare Opportunities Conference in New York City on Oct. 12, 2023. The event will provide pre-qualified institutional investors and healthcare industry professionals the opportunity to interact closely with C-level executives of approximately 25 public companies selected by ROTH’s research analysts. With a multiple sub-sector focus, the conference will feature participating companies operating in biotechnology, pharmaceuticals, medical technologies and oncology therapeutics. “Meaningful conversations between companies and a wide spectrum of investors will be the main focus of our Healthcare Opportunities…

Continue Reading

FridayOct 06, 2023 11:39 am

BioMedNewsBreaks – Safety Shot Holdings Inc. (NASDAQ: SHOT) Announces Ring Sponsorship of Jorge Masvidal’s Gamebred Bareknuckle MMA

Safety Shot (NASDAQ: SHOT) today announced its entry into an agreement with mixed martial arts (“MMA”) superstar Jorge Masvidal’s Gamebred Bareknuckle MMA, the world’s first bareknuckle MMA promotion. Over the next year, Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity, will be the ring sponsor for 12 Gamebred Bareknuckle matches. “Jorge is a superstar in the MMA world with a huge following and his Gamebred Bareknuckle fight promotion has garnered a fast growing following with millions of people viewing matches online and live audiences cheering at…

Continue Reading

ThursdayOct 05, 2023 12:06 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has released top-line results for its phase 2a trial of its investigational product Lomecel-B(TM). The study evaluated Lomecel-B for the treatment of mild Alzheimer’s disease. According to the report, the primary endpoint of safety was met across all study groups; in addition, the secondary endpoint of change from baseline to week 39 in Composite Alzheimer’s Disease Score (“CADS”) also demonstrated positive results. The report also noted that other doses demonstrated numerical…

Continue Reading

ThursdayOct 05, 2023 11:45 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS

Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, was awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”), a division of the National Institutes of Health (“NIH”). The grant is to support an Expanded Access Protocol (“EAP”) for the company’s investigational drug, CNM-Au8(R), in amyotrophic lateral sclerosis (“ALS”). Also referred to as Compassionate Use, an EAP is an FDA-regulated pathway that allows people with a serious and life-threatening disease to access an investigational drug that is not yet approved by the U.S.…

Continue Reading

ThursdayOct 05, 2023 10:54 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into a definitive agreement with Celly Nutrition Corp. According to the announcement, the Oct. 4, 2023, agreement outlines the distribution of a portion of FSD Pharma's shareholdings of Celly Nu to certain securityholders of FSD Pharma. The company noted that it has scheduled a virtual meeting on Nov. 20, 2023, for FSD Pharma securityholders to consider and vote on a special resolution approving the agreement, or plan of arrangement. A prerevenue, early-stage research and development company,…

Continue Reading

WednesdayOct 04, 2023 2:59 pm

BioMedNewsBreaks – Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) Starts Trading After TradeUP Acquisition Corp., Estrella Biopharma Inc. Business Combination

Estrella Immunopharma (NASDAQ: ESLA, ESLAW), formerly known as TradeUP Acquisition Corp. (“UPTD”), has successful closed a business combination with Estrella Biopharma Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company focused on developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. According to the announcement, shares in the combined company — Estrella Immunopharma — began trading on Oct. 2, 2023; in addition, all remaining UPTD units will separate into their underlying components, consisting of one share of combined company's common stock and one-half of one warrant. The combined company brings together capital and a…

Continue Reading

WednesdayOct 04, 2023 2:12 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Dismissal of Motion, Wins $2.8 Million Award

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting on the status of court action filed against it. The company announced that the Ontario Superior Court of Justice dismissed the motion to set aside an arbitration award to FSD Pharma; the motion was filed by Dr. Raza Bokhari, former FSD Pharma CEO of FSD Pharma and current CEO of Medicus Pharma Ltd. In addition, the company noted an earlier decision by the Honourable J. Douglas…

Continue Reading

WednesdayOct 04, 2023 1:59 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lung Cancer Treatment at 2023 AACR-NIH-EORTC Conference

Genprex (NASDAQ: GNPX) is at the forefront of pioneering cancer treatments, and it’s making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical and preclinical data at the prestigious 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15 at the Hynes Convention Center in Boston. The Acclaim-1 Phase 1 study results have demonstrated the safety and efficacy of REQORSA(R) in combination with Tagrisso(R), bringing hope to patients with late-stage NSCLC. Moreover, preclinical studies have highlighted REQORSA(R)'s potential in combination with a checkpoint inhibitor to combat chemotherapy-resistant small cell lung…

Continue Reading

WednesdayOct 04, 2023 11:50 am

BioMedNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) to Present at Upcoming Dawson James Conference

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that it will present at the 8th Annual Dawson James Conference taking place at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida, on Thursday, Oct. 12, 2023. NextPlat Corp’s executive chairman and CEO Charles M. Fernandez will deliver the company’s presentation and conduct in-person, one-on-one meetings throughout the conference. Fernandez’s presentation is slated to begin at 11 a.m. ET in Preserve Ballroom C. To view the full press release, visit https://ibn.fm/3eEUL About NextPlat Corp. NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors…

Continue Reading

WednesdayOct 04, 2023 10:23 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at CPHI Barcelona 2023, Other Upcoming Events

Scinai Immunotherapeutics (NASDAQ: SCNI) today announced that it will showcase its CDMO services at CPHI Barcelona, one of the international pharmaceutical industry’s premier trade shows, taking place Oct. 24 to 26. Scinai’s CDMO offers upstream and downstream process development and scale-up for protein-based drugs, analytical method development, and cGMP manufacturing including aseptic filling to biopharmaceutical and biotech clients. According to the announcement, several members of Scinai’s executive leadership team will be available to meet with potential partners and clients of the company’s end-to-end biologics CDMO service. Interested parties may request one-to-one meetings through the CPHI partnering platform, accessible to participants…

Continue Reading